Construction and validation of a nomogram model for predicting response to initial radioiodine therapy in differentiated thyroid cancer patients using serum cytokines combined with serum thyroglobulin - Scorecard - MDSpire

Construction and validation of a nomogram model for predicting response to initial radioiodine therapy in differentiated thyroid cancer patients using serum cytokines combined with serum thyroglobulin

  • By

  • Guohua Qin

  • AiQiang Dong

  • Ning Wang

  • Xinfeng Liu

  • Yingying Zhang

  • Guoqiang Wang

  • Chenghui Lu

  • Jiao Li

  • Na Han

  • ZengHua Wang

  • Zengmei Si

  • Fengqi Li

  • Rui Wang

  • Congcong Wang

  • Xufu Wang

  • June 2, 2026

  • 0 min

Share

Clinical Scorecard: Development and validation of a nomogram for forecasting treatment response to initial radioiodine therapy in patients with differentiated thyroid cancer based on serum cytokine levels and thyroglobulin measurements

At a Glance

CategoryDetail
Condition
Key MechanismsSerum cytokines and thyroglobulin levels as predictors of treatment response to radioactive iodine therapy.
Target Population
Care Setting

Key Highlights

  • Study involved 429 patients with intermediate- or high-risk DTC.
  • Independent predictors identified: serum thyroglobulin and serum interferon-alpha.
  • Nomogram model developed and validated for predicting treatment response.

Guideline-Based Recommendations

Diagnosis

  • Patients classified according to the 2025 ATA risk stratification system.

Management

  • Postoperative radioiodine therapy should be individualized based on risk of recurrence.

Monitoring & Follow-up

  • Follow-up data collected 6 to 12 months post-treatment to assess response.

Risks

  • Patients with intermediate- or high-risk DTC may have residual thyroid tissue.

Patient & Prescribing Data

Patients with intermediate- or high-risk non-distant metastatic DTC.

Serum cytokine levels may influence the therapeutic effect of initial RAI.

Clinical Best Practices

    Related Resources & Content

    Original Source(s)

    Construction and validation of a nomogram model for predicting response to initial radioiodine therapy in differentiated thyroid cancer patients using serum cytokines combined with serum thyroglobulin

    • by Guohua Qin, AiQiang Dong, Ning Wang, Xinfeng Liu, Yingying Zhang, Guoqiang Wang, Chenghui Lu, Jiao Li, Na Han, ZengHua Wang, Zengmei Si, Fengqi Li, Rui Wang, Congcong Wang, Xufu Wang

    • June 2, 2026

    Related Content

    Case Report: Tumor regression and neurological recovery in paraplegia from POLD1-mutated hepatocellular carcinoma treated with targeted immunotherapy and electroacupuncture

    This Week’s Biopharma News: New Approvals, Appeals, and AI

    Datroway and Hepcludex secure notable FDA approvals, while Outlook wins its bevacizumab appeal, BioMarin reports phase 3 VOXZOGO data, and BMS partners with Anthropic

    • June 2, 2026

    • 5 min
    Case series analysis of immunophenotypic evolution during recurrence of low-grade endometrial stromal sarcoma: implications for molecular stability and clinical management